July is off to a slow start at FDA, but the month is likely to heat up as a number of applications reach their user fee goal dates – including at least five new molecular or biologic entities.
Insys Therapeutics Inc.’s dronabinol oral solution Syndros is the first, and so far only, NDA approved by the Center...





